Please assess the completion status of the following clinical trial:

Trial Title: Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Participants Must:~* Have a diagnosis of XSCID~* Be between 2 years to 20 years old and have not completed puberty~* Consent to permit blood and/or tissue samples for storage~* Demonstrate short stature: height below the 3 rd percentile for chronological age~* Have a primary care physician at home~* Demonstrate growth failure, defined as growth velocity (measured as linear growth) that is less than 5% to 10% of that expected for children of the same age group, over the past 12 months~* Willingness to remain hospitalized for several days~* Provide evidence of serum IGF-1 level performed within the preceding 6 months and the results fall below normal limits for age~EXCLUSION CRITERIA:~Participants Must NOT:~* Have fusion of epiphyseal plates~* Demonstrate any history of anaphylactic reaction or hypersensitivity to mecasermin or any component of the drug's formulation~* Have any active or suspected neoplasia~* Demonstrate signs of intracranial hypertension as evidenced by papilledema upon examination by fundoscopy~* Have any condition that, in the investigator's opinion, places the patient at undue risk by participating in the study~* Be unwilling to undergo testing or procedures associated with this protocol

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).